IAIsadora Asunis

Isadora Asunis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Isadora Asunis has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Sardinian founder mutation in glycoprotein Ib platelet subunit beta (GP1BB) that impacts thrombocytopenia

    by Fabio Busonero, Maristella Steri, Valeria Orrù, Gabriella Sole, Stefania Olla, Michele Marongiu, Andrea Maschio, Carlo Sidore, Sandra Lai, Antonella Mulas, et al.


  • Induction of therapeutic levels of HbF in genome‐edited primary β039‐thalassaemia haematopoietic stem and progenitor cells

    by Maura Mingoia, Cristian A. Caria, Lin Ye, Isadora Asunis, M. Franca Marongiu, Laura Manunza, M. Carla Sollaino, Jiaming Wang, Annalisa Cabriolu, Ryo Kurita, et al.

    Summary: Hereditary persistence of fetal haemoglobin (HPFH) is the major modifier of the clinical severity of β‐thalassaemia. The homozygous mutation c.‐196 C>T in the Aγ‐globin (HBG1) promoter, which causes Sardinian δβ0‐thalassaemia, is able to completely rescue the β‐major thalassaemia phenotype caused by the β039‐thalassaemia mutation, ensuring high levels of fetal haemoglobin synthesis during adulthood. Here, we describe a CRISPR/Cas9 genome‐editing approach, combined with the non‐homologous end joining (NHEJ) pathway repair, aimed at reproducing the effects of this naturally occurring HPFH mutation in both HBG promoters. After selecting the most efficient guide RNA in K562 cells, we edited the HBG promoters in human umbilical cord blood‐derived erythroid progenitor 2 cells (HUDEP‐2) and in haematopoietic stem and progenitor cells (HSPCs) from β0‐thalassaemia patients to assess the therapeutic potential of HbF induction. Our results indicate that small deletions targeting the −196‐promoter region restore high levels of fetal haemoglobin (HbF) synthesis in all cell types tested. In pools of HSPCs derived from homozygous β039‐thalassaemia patients, a 20% editing determined a parallel 20% increase of HbF compared to unedited pools. These results suggest that editing the region of HBG promoters around the −196 position has the potential to induce therapeutic levels of HbF in patients with most types of β‐thalassaemia irrespective of the β‐globin gene (HBB) mutations.


  • Open Access

    A Sardinian founder mutation in GP1BB that impacts thrombocytopenia

    by Fabio Busonero, Maristella Steri, Valeria Orrù, Gabriella Sole, Stefania Olla, Michele Marongiu, Carlo Sidore, Sandra Lai, Antonella Mulas, Andrea Maschio, et al.

    To investigate the genetic regulation of platelet (PLT) levels we carried out a whole-genome association analysis in 6,528 Sardinians from the general population of the Lanusei valley. We found 6 variants significantly influencing PLT levels, including a novel rare missense mutation (p.Pro27Ser) in the GP1BB protein that is associated with PLT reduction (P=1.17×10 −16 ). This mutation is rare in the SardiNIA population cohort (frequency of 0.45%), even rarer in the rest of the Sardinian island (frequency of 0.16%), and not reported elsewhere. Notably, GP1BB is involved in Bernard-Soulier syndrome (BSS), a rare autosomal recessive bleeding disorder caused by a defect in the platelet GPIb-IX-V protein complex. Consistently, the 57 identified individuals heterozygous for the p.P27S mutation showed mild thrombocytopenia, morphologically enlarged platelets (P=2.13×10 −10 ), and reduced expression of two GPIb-IX-V-complex components: GPIbα (−26.51%, P=3.66×10 −8 ) and GPIX (−24.69%, P=2.66×10 −6 ). Molecular modeling infers a corresponding reduction in the stability of GP1BB. These observations predict that in homozygosity as well as in individuals carrying specific compound heterozygous configurations, this variant likely causes BSS.